[go: up one dir, main page]

MXPA05013142A - Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer. - Google Patents

Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.

Info

Publication number
MXPA05013142A
MXPA05013142A MXPA05013142A MXPA05013142A MXPA05013142A MX PA05013142 A MXPA05013142 A MX PA05013142A MX PA05013142 A MXPA05013142 A MX PA05013142A MX PA05013142 A MXPA05013142 A MX PA05013142A MX PA05013142 A MXPA05013142 A MX PA05013142A
Authority
MX
Mexico
Prior art keywords
pyridino
compounds
pyrimidin
anticancer agents
alone
Prior art date
Application number
MXPA05013142A
Other languages
English (en)
Inventor
Manoj C Desai
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of MXPA05013142A publication Critical patent/MXPA05013142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de piridino[1,2-a]pirimidinilo, sales aceptables farmaceuticamente y profarmacos de los mismos; composiciones que incluyen un portador aceptable farmaceuticamente y uno o mas de los compuestos piridino[1,2-a]pirimidinilo, ya sea solos o en combinacion con por lo menos un agente terapeutico adicional. Metodos para usar los compuestos piridino[1,2-a]pirimidinilo, ya sea solos o en combinacion con por lo menos un agente terapeutico adicional, en la profilaxis o tratamiento de enfermedades proliferativa.
MXPA05013142A 2003-06-20 2004-06-17 Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer. MXPA05013142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48018003P 2003-06-20 2003-06-20
PCT/US2004/019158 WO2004113335A2 (en) 2003-06-20 2004-06-17 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents

Publications (1)

Publication Number Publication Date
MXPA05013142A true MXPA05013142A (es) 2006-03-17

Family

ID=33539266

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013142A MXPA05013142A (es) 2003-06-20 2004-06-17 Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.

Country Status (15)

Country Link
US (1) US7326711B2 (es)
EP (1) EP1636225B1 (es)
JP (1) JP2007520435A (es)
KR (1) KR20060069356A (es)
CN (1) CN1809563A (es)
AT (1) ATE458735T1 (es)
AU (1) AU2004249730A1 (es)
CA (1) CA2528771A1 (es)
DE (1) DE602004025698D1 (es)
ES (1) ES2339862T3 (es)
IL (1) IL172192A0 (es)
MX (1) MXPA05013142A (es)
PT (1) PT1636225E (es)
TW (1) TW200503719A (es)
WO (1) WO2004113335A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083143A1 (en) * 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR20060135781A (ko) * 2004-02-25 2006-12-29 라 졸라 파마슈티칼 컴파니 질병의 치료를 위한 아민 및 아미드
US7504405B2 (en) 2004-04-06 2009-03-17 Novartis Vaccines And Diagnostics, Inc. Mitotic kinesin inhibitors
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006008523A1 (en) * 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones usefuel in the treatment and the prevention of cancer
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
MX2007001953A (es) * 2004-08-18 2007-05-09 Astrazeneca Ab Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
JP2008510734A (ja) * 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
KR20080006614A (ko) * 2005-04-14 2008-01-16 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 증식 질환의 치료에 유용한 ｈｓｐ90 억제제인2-아미노-퀴나졸린-5-온
US7799795B2 (en) 2005-06-27 2010-09-21 Amgen Inc. Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
KR20090097210A (ko) 2007-01-05 2009-09-15 노파르티스 아게 키네신 방추체 단백질 (ｅｇ－５) 억제제로서의 이미다졸 유도체
MX2011013816A (es) * 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
PE20142364A1 (es) * 2012-02-10 2015-01-10 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
JP6092264B2 (ja) 2012-03-01 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋委縮症を処置するための化合物
WO2013142236A1 (en) 2012-03-23 2013-09-26 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
PE20180129A1 (es) 2015-02-27 2018-01-18 Incyte Corp Sales de inhibidor de pi3k y procesos de preparacion
JP6847851B2 (ja) * 2015-04-15 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
EP3298017B1 (en) * 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
AU2017363369A1 (en) 2016-11-28 2019-05-30 Ptc Therapeutics, Inc Methods for modulating RNA splicing
BR112019025740A2 (pt) 2017-06-05 2020-06-23 Ptc Therapeutics, Inc. Compostos para tratar a doença de huntington
US11608501B2 (en) 2017-06-14 2023-03-21 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
CN108191860B (zh) * 2018-02-12 2019-12-10 中国医科大学 一种HIF-2α小分子抑制剂及其用途
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
KR20210018328A (ko) 2018-06-01 2021-02-17 인사이트 코포레이션 Pi3k 관련 장애의 치료를 위한 투여 요법
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
AU2019294482B2 (en) 2018-06-27 2022-09-01 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203913T1 (de) * 1993-05-31 2001-08-15 Kaken Pharma Co Ltd Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
GB2307177A (en) 1995-11-15 1997-05-21 Agrevo Uk Ltd Fungicidal pyridopyrimidines
MXPA02004162A (es) 1999-10-27 2003-08-20 Cytokinetics Inc Metodo y composiciones que utilizan quinazolinonas.
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002083143A1 (en) 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists
CA2440219A1 (en) * 2001-02-21 2002-10-17 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
JP2005511581A (ja) * 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
CA2468156A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
WO2004064741A2 (en) * 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
EP1636225A2 (en) 2006-03-22
DE602004025698D1 (de) 2010-04-08
JP2007520435A (ja) 2007-07-26
CA2528771A1 (en) 2004-12-29
WO2004113335A2 (en) 2004-12-29
PT1636225E (pt) 2010-05-03
US20050085490A1 (en) 2005-04-21
AU2004249730A1 (en) 2004-12-29
US7326711B2 (en) 2008-02-05
ES2339862T3 (es) 2010-05-26
ATE458735T1 (de) 2010-03-15
WO2004113335A3 (en) 2005-03-24
TW200503719A (en) 2005-02-01
CN1809563A (zh) 2006-07-26
IL172192A0 (en) 2006-04-10
KR20060069356A (ko) 2006-06-21
EP1636225B1 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
MXPA05013142A (es) Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
IL175714A0 (en) Quinazolinone compounds as anticancer agents
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2004006859A3 (en) Platinum compound
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
TW200718689A (en) 2-Amino-quinazolin-5-ones
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
IL256054A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
TNSN08143A1 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones
PT1416935E (pt) Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina
BG106586A (en) Pyrazolopyramidines as therapeutic agents
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
PL1684763T3 (pl) 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
MXPA05008490A (es) Combinaciones que contienen imidazopiridinas y su uso en el tratamiento de enfermedades gastrointestinales inflamatorias.

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration